July 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, which includes a strategic investment from Illumina and structured financing from Soleus Capital, as well as investments from existing investors. The proceeds will be leveraged to advance commercial activities, including infrastructure to support biopharma partnerships, and expand adoption of its distributable clinical testing kits.
Pillar Biosciences, 508-655-3027